OR WAIT null SECS
July 02, 2025
Article
Our recap of the first half of 2025 highlights 5 regulatory updates, 5 trial announcements, and 3 top perspectives in eyecare.
July 01, 2025
Our Q2 2025 recap for ophthalmology highlights 5 regulatory updates, 5 important trial announcements, and top perspectives in eyecare.
June 30, 2025
June was characterized by HCPLive’s coverage of the AOA 2025 Conference in Minneapolis and a host of cross-specialty disease indicators and drug uses.
June 02, 2025
This May was characterized by HCPLive’s coverage of the ARVO and Envision conferences, as well as a slew of FDA approvals towards the end of the month.
May 25, 2025
Type 2 macular neovascularization, reductions in outer nuclear layer and central foveal thickness, and intraretinal fluid may indicate higher odds of retinal atrophy.
May 15, 2025
Recent data from the GALE trial align with OAKS and DERBY results, indicating a successful treatment of geographic atrophy.
May 14, 2025
Video
Goldberg’s post hoc analysis has indicated that AREDS and AREDS2 vitamins do not slow either GA progression to the fovea or overall GA growth.
May 10, 2025
Stay updated with the latest healthcare breakthroughs, including cholesterol treatments and innovative therapies for AMD and psoriasis, in this week's roundup.
May 09, 2025
The recent trial indicates that the oral treatment gildeuretinol reduces GA lesion growth rates, as well as achieving better BCVA scores.
May 08, 2025
Data released by Cognition Therapeutics shows that oral zervimesine resulted in substantially reduced lesion growth over 18 months compared to placebo.
